ARNA Stock Recent News Arena Pharmaceuticals (ARNA) 4.53 11/14/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arena Pharmaceuticals (ARNA) 4.53 $ARNA

Belviq Weekly Sales Come In Flat
Spencer Osborne - at Seeking Alpha - 1 hr 41 mins ago

ARNA: 4.53 (-0.08)

Belviq For Smoking Cessation - Sizzle Or Smolder?
Spencer Osborne - at Seeking Alpha - Fri Nov 14, 9:24AM CST

ARNA: 4.53 (-0.08)

ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST

OREX: 5.65 (-0.21), HLF: 38.50 (+0.65), NVO: 44.13 (+0.11), VVUS: 3.25 (-0.01), AMGN: 157.68 (-3.17), GSK: 45.74 (+0.08), ARNA: 4.53 (-0.08)

Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 13, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), at The New York Palace Hotel in New York.
ARNA: 4.53 (-0.08)

Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:27AM CST
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
ARNA: 4.53 (-0.08)

Arena Pharmaceuticals' (ARNA) Presents at Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 9:32PM CST

ARNA: 4.53 (-0.08)

Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST

OREX: 5.65 (-0.21), VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically,  Arena Pharmaceuticals '   Belviq and  VIVUS 's   Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.34 (-0.08), VVUS: 3.25 (-0.01), GSK: 45.74 (+0.08), ARNA: 4.53 (-0.08)

Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.65 (-0.21), VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST

OREX: 5.65 (-0.21), VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.65 (-0.21), VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST

VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST

OREX: 5.65 (-0.21), VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST

VVUS: 3.25 (-0.01), ARNA: 4.53 (-0.08)

Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
PR Newswire - Thu Nov 06, 7:00AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts.
ARNA: 4.53 (-0.08)

Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Wed Nov 05, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time), at The Arizona Biltmore in Phoenix, Arizona.
ARNA: 4.53 (-0.08)

Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.25 (-0.01), AMAG: 34.00 (-0.24), ARNA: 4.53 (-0.08)

Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST

OREX: 5.65 (-0.21), ARNA: 4.53 (-0.08)

Arena Beats The Street On Taigen Stock Sale
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:26PM CST

ARNA: 4.53 (-0.08)

Arena Pharmaceuticals' (ARNA) CEO Jack Lief on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:53AM CST

ARNA: 4.53 (-0.08)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 4

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 4

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading

Top 5 Most Recently Viewed Articles

Vaccinex Unveils Efficacy Insights for Pepinemab in Alzheimer’s Study

Updated Category News Views 71

Vaccinex Provides Update on Pepinemab Study for Alzheimer’s Disease ROCHESTER, N.Y. — Vaccinex, Inc. (NASDAQ: VCNX), a forward-thinking biotechnology firm, is making significant strides in the treatment of Alzheimer's disease (AD) and cancer. The company is focused on a unique approach through the inhibition of Semaphorin 4D (SEMA4D). Recently, it was announced that...

Continue Reading
Legal Inquiry into Netflix, Inc. (NFLX) Attracts Investor Attention

Updated Category News Views 287

Understanding the Investigation into Netflix, Inc. Recently, the law firm Robbins Geller Rudman & Dowd LLP has initiated a formal investigation into Netflix, Inc. (NASDAQ: NFLX). This inquiry primarily focuses on potential violations of U.S. federal securities laws that may have occurred within the company. The Implications for Investors This investigation comes at a...

Continue Reading
Norway's Wealth Fund Expands Portfolio with London Investment

Updated Category News Views 221

Norway's Sovereign Wealth Fund Takes Bold Step in London Norway's sovereign wealth fund, expertly managed by Norges Bank Investment Management, has recently made headlines with its strategic acquisition of a 25% stake in a notable portfolio of office and retail properties located in London's prestigious Mayfair district. Significant Investment in a Prime Location This...

Continue Reading
Exagen Inc. Announces New Biomarkers and Financial Success

Updated Category News Views 291

Exagen Inc. Introduces Groundbreaking Biomarkers for Autoimmune Diseases Innovative testing aims to enhance patient diagnosis and care Exagen Inc. (Nasdaq: XGN), a pioneering company in autoimmune testing, has achieved a significant milestone by receiving conditional approval from the New York State Department of Health for its advanced assays to diagnose systemic lupus...

Continue Reading
Pacaso's Financial Growth in 2025: A Closer Look At Results

Updated Category News Views 1306

Pacaso Shows Promising First Half Financial Performance Pacaso, the innovative platform for co-owned luxury vacation homes, has recently shared its financial results for the first half of 2025, demonstrating strong stability and improved efficiency despite a challenging broader housing market. The company reported an impressive adjusted gross profit while managing to...

Continue Reading